Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer

Cancer Biother Radiopharm. 2004 Feb;19(1):81-4. doi: 10.1089/108497804773391711.


Aim of this work was to asses whether a novel 99mTc labeled Bombesin (BN) can play a clinical role in diagnosis and staging of prostate cancer. 14 patients were studied with trans-rectal ultrasonography-guided biopsy, CT and MRI and with 99mTc BN Scintigraphy. Five patients were also imaged by 111In Octreotide (O) scan. All the patients but one were submitted to surgery and final diagnosis was reached by pathology, taken as the gold standard method. Two patients showed benign adenoma and 12 patients showed cancer at biopsy. 99mTc BN SPECT was positive in all 12 patients with cancer. Four of these patients also showed pelvic focal uptake, referred to inguinal lymph-nodal involvement. MRI and CT provided similar findings in only three cases. Pathologic evaluation after operation confirmed the invasion of nodes in all four subjects. Both 99mTc BN and 111In O scans provided normal findings in the two subjects affected by benign adenoma, while 111In O was positive in only two of three patients with cancer and was always unable to detect nodal invasion. These preliminary data suggest that 99mTc BN SPECT scan could be useful to detect primary prostate cancer and to reveal loco-regional node involvement.

Publication types

  • Clinical Trial

MeSH terms

  • Bombesin*
  • Humans
  • Image Processing, Computer-Assisted
  • Lymphatic Metastasis / diagnosis
  • Magnetic Resonance Imaging
  • Male
  • Neoplasm Staging
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / pathology
  • Technetium*
  • Tomography, Emission-Computed, Single-Photon
  • Ultrasonography


  • Technetium
  • Bombesin